BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21315698)

  • 1. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine.
    Chen CW; Lee YP; Wang YF; Yu CK
    Vaccine; 2011 Mar; 29(15):2772-6. PubMed ID: 21315698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines.
    Vesikari T; Joensuu J; Baer M; Käyhty H; Olander RM; Sormunen H; Miettinen A; Ward RL; Guillot T
    Acta Paediatr; 1999 May; 88(5):513-20. PubMed ID: 10426173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
    Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
    Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection.
    Bek EJ; Hussain KM; Phuektes P; Kok CC; Gao Q; Cai F; Gao Z; McMinn PC
    Vaccine; 2011 Jun; 29(29-30):4829-38. PubMed ID: 21550375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants].
    Sikora JP; Chlebna-Sokół D
    Przegl Lek; 2003; 60(11):699-703. PubMed ID: 15058036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Feb; 29(10):1913-20. PubMed ID: 21219984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
    Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
    Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys.
    Dong C; Liu L; Zhao H; Wang J; Liao Y; Zhang X; Na R; Liang Y; Wang L; Li Q
    Vaccine; 2011 Aug; 29(37):6269-75. PubMed ID: 21722686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
    Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
    Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
    Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.